Location of Repository

Radiotherapy for metastatic fibrolamellar hepatocellular carcinoma

By Justin G. Peacock, Jason A. Call and Kenneth R. Olivier


Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare variant of hepatocellular carcinoma (HCC) that commonly affects young individuals without a prior history of liver disease. FLHCC commonly results in a better prognosis than HCC; however, the risk of recurrence and metastatic disease is high. FLHCC is typically treated by primary resection of the tumor with 50-75% cure rates. The use of radiation therapy in FLHCC has not been assessed on its own, and may show some success in a very few reported combination therapy cases. We report on the successful use of radiation therapy in a case of metastatic FLHCC to the lung following primary and secondary resections. Our treatment of the large, metastatic, pulmonary FLHCC tumor with 40 Gy in 10 fractions resulted in an 85.9% tumor volume decrease over six months. This suggests FLHCC may be a radiosensitive tumor and radiotherapy may be valuable in unresectable or metastatic tumors

Topics: radiotherapy, fibrolamellar, hepatocellular carcinoma, Medicine, R, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Publisher: PAGEPress Publications
Year: 2013
DOI identifier: 10.4081/rt.2013.e28
OAI identifier: oai:doaj.org/article:17f182ee7498426f8d8e6633300761b5
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/2036-3613 (external link)
  • https://doaj.org/toc/2036-3605 (external link)
  • http://www.pagepress.org/journ... (external link)
  • https://doaj.org/article/17f18... (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.